Search | IOVS | ARVO Journals

Showing 1 – 20 of 27

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

AXITINIB TO TREAT DIABETIC RETINOPATHY: A DRUG REPURPOSING STUDY

Claudio Bucolo; Francesca Lazzara; Federica Conti; Pradip K Sasmal; Shanavas Alikunju; Settimio Rossi; Chiara B M Platania; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4584.

ARVO Annual Meeting Abstract June 2023

VITAMIN D 3 AND RETINAL PROTECTION: AN IN VITRO STUDY

Federica Conti; Francesca Lazzara; Anna Maria Longo; Chiara Bianca Maria Platania; Filippo Drago; Settimio Rossi; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3499.

Retina January 2023

Safety Profile of Lutein- Versus Triamcinolone Acetonide–Based Vitreous Staining

PDF

Francesca Lazzara; Federica Conti; Mariantonia Ferrara; Myrta Lippera; Michele Coppola; Settimio Rossi; Filippo Drago; Claudio Bucolo; Mario R. Romano
TAGS: cytotoxicity, lutein, safety, triamcinolone acetonide, vitreous body, cellular morphology
Trans. Vis. Sci. Tech.. 2023; 12(1):5. https://doi.org/10.1167/tvst.12.1.5

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2022

PHARMACOLOGICAL AND SAFETY PROFILE OF TWO NEW BETAMETHASONE/CHLORAMPHENICOL GEL OPHTHALMIC FORMULATIONS

Claudio Bucolo; Francesca Lazzara; Giovanni Luca Romano; Federica Conti; Cateno Piazza; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2112 – F0128.

ARVO Annual Meeting Abstract June 2021

VITAMIN D3 AND MESO-ZEAXANTHIN COMBINATION PROTECTS HUMAN RETINAL PIGMENTED EPITHELIAL CELLS IN AMD

Claudio Bucolo; Francesca Lazzara; Federica Conti; Chiara B M Platania; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):203.

ARVO Annual Meeting Abstract June 2021

OCULAR SAFETY PROFILE OF A NEW FORMULATION BASED ON HYPOCHLOROUS ACID IN RABBIT EYE

Giovanni Luca Romano; Francesca Lazzara; Federica Conti; Salvatore Giunta; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):726.

ARVO Annual Meeting Abstract June 2020

Small molecules to treat angiogenesis and inflammation in an in-vitro model of diabetic retinopathy

Chiara B M Platania; Valeria Pittalà; Alessia Pascale; Gabriella Lupo; Carmelina Daniela Anfuso; Nicoletta Marchesi; Martina Cristaldi; Melania Olivieri; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1878.

ARVO Annual Meeting Abstract June 2020

VITAMIN D3 AND MESO ZEAXANTHIN PROTECT RETINAL PIGMENTED EPITHELIAL CELLS FROM β-AMYLOID DAMAGE

Claudio Bucolo; Francesca Lazzara; Federica Conti; Chiara B M Platania; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4928.

ARVO Annual Meeting Abstract July 2019

NEW FORMULATIONS BASED ON INNOVATIVE BRILLIANT BLUE G DERIVATIVE TO STAIN RETINAL MEMBRANES

Claudio Bucolo; Filippo Drago; Mario R Romano; Marco Rao; Angelo Spadaro

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):39.

ARVO Annual Meeting Abstract July 2019

SELECTIVE ANTI-PlGF PROTECTS HUMAN RETINAL ENDOTHELIAL CELLS AGAINST HIGH GLUCOSE

Francesca Lazzara; Annamaria Fidilio; Chiara Bianca Maria Platania; Federica Conti; Salvatore Salomone; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5371.

ARVO Annual Meeting Abstract July 2018

RETINAL BIOAVAILABILITY OF DIFFERENT CURCUMIN ORAL FORMULATIONS: A TRANSLATIONAL STUDY

Claudio Bucolo; Chiara B M Platania; Anna Fidilio; Francesca Lazzara; Cateno Piazza; Federica Geraci; Salvatore Salomone; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):193.

ARVO Annual Meeting Abstract June 2017

HUMAN RETINAL PERICYTES PROTECTION: ROLE OF P2X7 RECEPTOR

Claudio Bucolo; Chiara B M Platania; Giovanni Giurdanella; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5804.

ARVO Annual Meeting Abstract June 2017

Drug discovery targeting HuR protein: small molecules to treat diabetic retinopathy

Chiara B M Platania; Valeria Pittalà; Alessia Pascale; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5801.

ARVO Annual Meeting Abstract September 2016

Exploring ligands selectivity toward human P2X7 receptor: application to drug discovery in ophthalmology

Chiara B M Platania; Federica Geraci; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract September 2016

PROTECTIVE EFFECTS OF TGF-β1 AGAINST AMYLOID-β 1-42 OLIGOMERS-INDUCED RETINAL DAMAGE

Claudio Bucolo; Vincenzo Fisichella; Giovanni Giurdanella; Chiara Bianca Maria Platania; Giovanni Luca Romano; Federica Geraci; Filippo Drago

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):119.

ARVO Annual Meeting Abstract June 2015

Common miRNAs in Alzheimer’s disease and retinal degenerative diseases

Giovanni Luca Romano; Chiara B M Platania; Stefano Forte; Salvatore Salomone; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2275.

ARVO Annual Meeting Abstract June 2015

Role of Homocysteine in Retinal Neurodegeneration

Giulia Malaguarnera; Shereen Nizari; Lisa Turner; James Brodie; Benjamin Davis; Li Guo; Eduardo M Normando; Claudio Bucolo; Filippo Drago; M Francesca Cordeiro

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2369.

ARVO Annual Meeting Abstract April 2014

Molecular features of interaction between VEGF-A and anti-angiogenic molecules

Chiara B M Platania; Salvatore Salomone; Filippo Drago; Claudio Bucolo

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1943.

ARVO Annual Meeting Abstract April 2014

INTERACTIONS OF GASEOUS NEUROMODULATORS IN THE CONTROL OF RABBIT OPHTHALMIC VASCULAR TONE

Claudio Bucolo; Roberta Foresti; Giovanni Giurdanella; Filippo Drago; Salvatore Salomone

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4357.

ARVO Annual Meeting Abstract April 2014

Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy

Giulia Malaguarnera; Caterina Gagliano; Joana Margarida Galvao; Claudio Bucolo; Filippo Drago; M Francesca Cordeiro; Teresio Avitabile

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4404.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

AXITINIB TO TREAT DIABETIC RETINOPATHY: A DRUG REPURPOSING STUDY

VITAMIN D 3 AND RETINAL PROTECTION: AN IN VITRO STUDY

Safety Profile of Lutein- Versus Triamcinolone Acetonide–Based Vitreous Staining

PHARMACOLOGICAL AND SAFETY PROFILE OF TWO NEW BETAMETHASONE/CHLORAMPHENICOL GEL OPHTHALMIC FORMULATIONS

VITAMIN D3 AND MESO-ZEAXANTHIN COMBINATION PROTECTS HUMAN RETINAL PIGMENTED EPITHELIAL CELLS IN AMD

OCULAR SAFETY PROFILE OF A NEW FORMULATION BASED ON HYPOCHLOROUS ACID IN RABBIT EYE

Small molecules to treat angiogenesis and inflammation in an in-vitro model of diabetic retinopathy

VITAMIN D3 AND MESO ZEAXANTHIN PROTECT RETINAL PIGMENTED EPITHELIAL CELLS FROM β-AMYLOID DAMAGE

NEW FORMULATIONS BASED ON INNOVATIVE BRILLIANT BLUE G DERIVATIVE TO STAIN RETINAL MEMBRANES

SELECTIVE ANTI-PlGF PROTECTS HUMAN RETINAL ENDOTHELIAL CELLS AGAINST HIGH GLUCOSE

RETINAL BIOAVAILABILITY OF DIFFERENT CURCUMIN ORAL FORMULATIONS: A TRANSLATIONAL STUDY

HUMAN RETINAL PERICYTES PROTECTION: ROLE OF P2X7 RECEPTOR

Drug discovery targeting HuR protein: small molecules to treat diabetic retinopathy

Exploring ligands selectivity toward human P2X7 receptor: application to drug discovery in ophthalmology

PROTECTIVE EFFECTS OF TGF-β1 AGAINST AMYLOID-β 1-42 OLIGOMERS-INDUCED RETINAL DAMAGE

Common miRNAs in Alzheimer’s disease and retinal degenerative diseases

Role of Homocysteine in Retinal Neurodegeneration

Molecular features of interaction between VEGF-A and anti-angiogenic molecules

INTERACTIONS OF GASEOUS NEUROMODULATORS IN THE CONTROL OF RABBIT OPHTHALMIC VASCULAR TONE

Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy

To View More...

You must be signed into an individual account to use this feature.